Northeast Financial Consultants’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Northeast Financial Consultants’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,130	Closed	-$101K	–	364
2022 Q1	$101K	Sell	10,130 -1,310	-11%	-$13.9K	0.01%	379
2021 Q4	$135K	Hold	11,440	–	–	0.01%	345
2021 Q3	$130K	Buy	+11,440	New	+$149K	0.01%	344
2020 Q3	–	Sell	-8,290	Closed	-$210K	–	307
2020 Q2	$210K	Buy	+8,290	New	+$173K	0.02%	264

Other funds holding KNSA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Northeast Financial Consultants's KNSA Position: Q2 2022 in Review

Northeast Financial Consultants sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2022, closing a stake of 10,130 shares — an estimated $101K sold.

Northeast Financial Consultants first reported a position in KNSA in Q2 2020 and held it in 4 quarters. The position peaked at $210K in Q2 2020. 92 funds tracked by Wall St. Rank hold KNSA as of Q2 2022.

Northeast Financial Consultants reported no remaining Kiniksa Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Northeast Financial Consultants sold 10,130 Kiniksa Pharmaceuticals shares in Q2 2022, an estimated $101K.
Northeast Financial Consultants first reported a position in Kiniksa Pharmaceuticals in Q2 2020 and held it in 4 quarters.
Northeast Financial Consultants's Kiniksa Pharmaceuticals position peaked at $210K in Q2 2020.
92 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2022.

Based on Northeast Financial Consultants's 13F filing for Q2 2022, filed 12 Aug 2022.